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Abstract 
Objective: The design of this study was due to the report of the antioxidant properties of Ellagic acid (EA) for its 
evaluation on the Insulin resistance (IR), oxidative stress and sex hormones levels in women with polycystic ovarian 
syndrome (PCOS).
Methods: In this randomized, double-blind, placebo-controlled clinical trial, 60 patients were recruited. Patients were 
randomly allocated consumed a capsule containing 200 mg of EA per day (n = 30) or placebo (n = 30) for 8 weeks. 
The fasting blood sugar (FBS), insulin, IR, total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), high 
density lipoprotein (HDL), total antioxidant capacity (TAC), Malondialdehyde (MDA), C-reactive protein (CRP), Tumor 
necrosis factor-alpha (TNF-α), sex hormones and anti-mullerian hormone (AMH) were measured at the beginning and 
end of the study.
Result: At the end of the study, the mean of FBS, insulin, IR, TC, TG, LDL, MDA, CRP, TNF-α, total testosterone, prolactin 
and AMH were significantly decreased in the intervention group compared to the placebo group (P < 0.05). Also, there 
was a significant increase in the mean of TAC after supplementation with EA (P < 0.05). At the end of the study, no 
significant changes were observed in the mean of anthropometric factors, physical activity and food intake (P > 0.05).
Conclusion: EA supplementation can be helpful as a diet supplement in women with PCOS through improvement 
in insulin resistance. This supplement may be used to reduce metabolic disorders in women.
Trial registration: This study was retrospectively (07–07-2019) registered in the Iranian website (www. irct. ir) for regis-
tration of clinical trials (IRCT2 01410 25019 669N12).
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and ultimately reducing sex hormones and lowering 
AMH [39]. One of the most effective factors in reduc-
ing IR is the use of plant polyphenols. So far, no clinical 
studies have examined the effects of EA polyphenol on 
mentioned factors, but some micronutrients have been 
studied with antioxidant properties. The results of Shokr-
pour et al. [40]. study indicated that receiving CoQ10 in 
women with PCOS significantly decreased the level of 
AMH. In this clinical trial, 30 women with PCOS con-
sumed CoQ10 pills 100 mg daily for 3 months. Also, in 
AbdulameerYahya et  al. [41]. study, taking the vitamin 
D and CoQ10 oral supplement in PCOS patients ame-
liorated the hormonal profile, oxidative marker, and 
ovulation outcome. Their results showed that these anti-
oxidants significantly decreased the LH and AMH after 
eight weeks. Also, studies that have examined the effects 
of IR-reducing drugs such as metformin in women with 
this syndrome have also reported a significant reduction 
in sex hormones such as LH, testosterone and AMH at 
the end of the study [42]. This clinical study, like other 
studies, can have strengths and weaknesses. One of 
the strengths of this study is that for the first time the 
effect of pure supplement of EA was investigated in 
women with PCOS. Also, the design of this study as a 
double-blind randomized clinical trial that had parallel 
groups, making the results of this study remarkable. It 
is also important to control confounder factors such as 
weight, physical activity, and food intake in studies that 
conducted on metabolic diseases, which was done in 
this research. However, due to the low budget and the 
limited number of participants and the duration of the 
intervention, the results of this study have been statisti-
cally analyzed, it should be noted that in order to draw 
clinical conclusions and examine the clinical effects, it 
is necessary to conduct studies with a larger number of 
participants and intervention period.
Conclusion
In conclusion, the results of this study indicated that 
8  weeks of supplementation with EA, 200  mg/day, 
reduced the levels of blood sugar, blood lipids and IR in 
PCOS patients. Also, with the ameliorating in the status 
of oxidative stress and inflammatory status, at the end of 
the study, we saw a significant decrease in the amount of 
AMH in these patients. These results provide evidence to 
support the view that polyphenol antioxidant group with 
reducing the biochemical factors, can play an important 
role in helping to control the condition of this syndrome. 
Nevertheless, further studies are needed to provide addi-
tional evidences.
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